DUBLIN--(BUSINESS WIRE)--The "Global Epigenetics Market - Segmented by Kits, Reagents, Enzymes, Instruments, Application, Technology, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
According to Cancer Research UK, in 2012, 14.1 million new cases of cancer were diagnosed worldwide. The World Health Organization estimated that this figure may rise to 35 million new cases in 2035. It is also estimated that nearly 550,000 new cases are diagnosed with head and neck cancer each year, across the world. It is estimated that nearly 6% of the malignancies occur in the United States.
According to the American Cancer society, nearly 40,000 people in the United States are diagnosed with head and neck cancer, of which 12,000 were supposed to die in the year 2014 alone. This depicts the large patient pool of cancer patients, which will propel the growth of the epigenetics market. The other factors, like increasing funding for R&D in healthcare and the rising epigenetic applications in non-oncology diseases, are driving the market.
The epigenetic instruments cost is rising gradually, and this increase is becoming one of the major restraints for the growth of the market. The instruments, such as mass spectrometers, sonicators, and the next generation sequences, are already costly, and the rising cost of these instruments are going to increase the cost for the genetic test, which simultaneously decreases the adoption rate of epigenetics. Also, the lack of skilled researchers is restraining the market growth of epigenetics.
In North America, the United States is dominating the epigenetics market due to the factors, such as increasing prevalence rate of cancer, increasing funding for the R&D, and the increasing collaborations between several large pharmaceutical companies for development of enhanced therapeutics. Asia-Pacific is expected to record a substantial growth over the forecast period.
Key Developments in the Market
- December 2017: Roche and Ignyta made definitive merger agreement
- December 2017: Zymo Research collaborated with Bertin
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
- Abcam Plc
- Active Motiff
- Diagenode Inc
- Illumina Inc
- Merck & Co.
- Sigma Aldrich Corporation
- Thermo Fisher Scientific
- Zymo Research Corporation
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/8bvnl3/global?w=4